We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
-16.36%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$1.67B
AUM Growth
-$505M
Cap. Flow
-$50.4M
Cap. Flow %
-3.01%
Top 10 Hldgs %
75.72%
Holding
51
New
6
Increased
12
Reduced
12
Closed
16

Top Buys

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$49.3M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$41.5M
3
ALLO icon
Allogene Therapeutics
ALLO
+$30M
4
AMRN
Amarin Corp
AMRN
+$27.9M
5
ZGNX
Zogenix, Inc.
ZGNX
+$21.2M

Top Sells

Rank Stock Value
1
ECYT
Endocyte, Inc. Common Stock
ECYT
+$94.2M
2
PBYI icon
Puma Biotechnology
PBYI
+$52.8M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$36.8M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$33.7M
5
CPRX
Catalyst Pharmaceutical
CPRX
+$17M

Sector Composition

Rank Sector Weight
1 Healthcare 84.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$253M 15.11%
17,714,461
– –
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$204M 12.17%
4,798,101
– –
SRPT icon
3
Sarepta Therapeutics
SRPT
$1.64B
$139M 8.32%
1,275,000
+331,500
+35% +$41.5M
ASND icon
4
Ascendis Pharma A/S
ASND
$16.6B
$124M 7.42%
1,980,000
+16,664
+0.8% +$1.05M
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$11.9B
$116M 6.92%
1,360,000
-8,103
-0.6% -$771K
FOLD
6
DELISTED
Amicus Therapeutics
FOLD
$97M 5.8%
10,125,000
+791,868
+8% +$8.7M
IOVA icon
7
Iovance Biotherapeutics
IOVA
$2.03B
$90.8M 5.43%
10,261,039
+1,598,319
+18% +$15.4M
HZNP
8
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$85M 5.08%
4,350,000
-110,426
-2% -$2.16M
ARGX icon
9
argenx
ARGX
$54.9B
$82.6M 4.94%
860,000
+104,585
+14% +$9.29M
AMRN
10
Amarin Corp
AMRN
$300M
$75.9M 4.54%
278,750
+76,500
+38% +$27.9M
ZGNX
11
DELISTED
Zogenix, Inc.
ZGNX
$72M 4.3%
1,975,000
+517,087
+35% +$21.2M
LOXO
12
DELISTED
Loxo Oncology, Inc
LOXO
$45.5M 2.72%
+325,000
New +$49.3M
TCDA
13
DELISTED
Tricida, Inc. Common Stock
TCDA
$41.3M 2.47%
1,750,000
-21,500
-1% -$618K
ALLO icon
14
Allogene Therapeutics
ALLO
$607M
$27.8M 1.66%
+1,128,584
New +$30M
MDGL icon
15
Madrigal Pharmaceuticals
MDGL
$12.4B
$25.4M 1.52%
225,000
-238,000
-51% -$36.8M
ASMB icon
16
Assembly Biosciences
ASMB
$494M
$22.6M 1.35%
83,333
-4,036
-5% -$1.17M
TGTX icon
17
TG Therapeutics
TGTX
$8.16B
$19.5M 1.16%
4,750,000
+549,969
+13% +$2.73M
INDP icon
18
Indaptus Therapeutics
INDP
$254M
$18.9M 1.13%
1,116
-32
-3% -$436K
BDSI
19
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$17.5M 1.05%
4,725,000
-712,779
-13% -$2.5M
PCRX icon
20
Pacira BioSciences
PCRX
$1.04B
$17.2M 1.03%
400,000
-13,196
-3% -$616K
XENE icon
21
Xenon Pharmaceuticals
XENE
$6.15B
$15.1M 0.91%
2,400,000
+32,782
+1% +$291K
GBT
22
DELISTED
Global Blood Therapeutics, Inc.
GBT
$14.4M 0.86%
350,000
+62,500
+22% +$2.34M
PTCT icon
23
PTC Therapeutics
PTCT
$6.12B
$13M 0.78%
380,000
-304,000
-44% -$10.9M
ESTA icon
24
Establishment Labs
ESTA
$2.67B
$13M 0.78%
475,000
– –
TLGT
25
DELISTED
Teligent, Inc
TLGT
$7.26M 0.43%
530,000
+57
+0% +$1.49K
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q4 2018 Portfolio in Review

As of Q4 2018, Avoro Capital Advisors held 51 positions worth $1.67B, down 23% from $2.18B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Avoro Capital Advisors withdrew a net $50.4M in Q4 2018, closing 16 positions and reducing 12 holdings. Its most notable exit was Endocyte, Inc. Common Stock, an estimated $94.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 83% a quarter earlier.

Against the trend, Avoro Capital Advisors opened a new position in Loxo Oncology, Inc worth $45.5M.

  • Avoro Capital Advisors's largest Q4 2018 buy was Loxo Oncology, Inc: 325,000 shares worth $45.5M.
  • Avoro Capital Advisors added most to Sarepta Therapeutics in Q4 2018, an estimated $41.5M increase.
  • Avoro Capital Advisors's biggest Q4 2018 reduction was Madrigal Pharmaceuticals, cutting an estimated $36.8M.
  • Avoro Capital Advisors fully exited Endocyte, Inc. Common Stock in Q4 2018, selling an estimated $94.2M.
  • Avoro Capital Advisors's ten largest holdings make up 76% of its $1.67B portfolio in Q4 2018.
  • Avoro Capital Advisors opened 6 new positions and closed 16 in Q4 2018.
  • Avoro Capital Advisors's portfolio value fell 23% quarter-over-quarter to $1.67B.

Based on Avoro Capital Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.